Risk of long acting beta-2 agonists in asthma;Riesgo de los broncodilatadores agonistas β2- adrenérgicos de acción prolongada en el asma bronquial

Medicina Clinica

Volumn 128, Issue 9, 2007, Pages 352-354

  Orriols, Ramón ^a   Vallano, Antonio ^b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Fundacion Institut Catala de Farmacologia   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLUCOCORTICOID; SALBUTAMOL; SALMETEROL;

ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG MECHANISM; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 34247165471     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13099804     Document Type: Article

References (23)

1. 2 adrenoreceptor agonists in asthma management. Respir Med. 2005;99:152-70.
2. 2- agonists in asthma: an overview of Cochrane systematic reviews. Respir Med. 2005;99:384-95.
3. National Institutes of Health. National Heart, Lung, and Blood Institute. Guidelines Initiative for Asthma. Global strategy for asthma management and prevention. Workshop Report, Updated October, 2005.
4. 2-agonists in asthma. Not so SMART? Drug Saf. 2006;29:647-56.
5. Sears MR, Taylor DR, Print GG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in asthma. Lancet. 1990;336:1391-
6. Sears MR, Taylor DR. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994; 11:259-83.
7. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular pyagonist use in patients with asthma. Ann Intern Med. 2004;140:802-13.
8. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilatador treatment. BMJ. 1993;306:1034-37.
9. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, and the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
10. Martinez FD. Safety of long-acting beta-agonists- An urgent need to clear the air. N Engl J Med. 2005;353:2637-9.
11. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70-4.
12. Salpeter S, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effects of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-12.
13. FDA Public Health Advisory. Serevent Diskus (salmetorol xinofate inhalation powder), Advair Diskus (fluticasone propionate & salmetorol inhalation powder, Foradil Aerolizer (formoterol fumarate inhalation powder) [citado 31 Ene 2006]. Disponible en: http://www.fda.gov/advisory/LAMA.htm
14. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists is there cause for concern? Drug Saf. 1997;16:295-308.
15. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Boushey HA, Deykin A, et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-26.
16. McIvor Ra, Pizzini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-30.
17. Green RH, Brightling CE, Mckenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-21.
18. Lee DK, Jackson CM, Bates CE, Lipworth BJ. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax. 2004;59:662-67.
19. Mjaanes CM, Whelan GJ, Szefler SJ. Corticosteroid therapy in asthma: predictors of responsiveness. Clin Chest Med. 2006;27:119-32.
20. Bisgaard H, Szefler S. Long-acting β2 agonists and paediatric asthma. Lancet. 2006;367:286-8.
21. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med. 1998; 158:S146-53.
22. Pizzichini E, Left JA, Reiss TF, Hendeles L, Boulet Lp, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomised, controlled trial. Eur Respir J. 1999;14:12-8.
23. Lipworth BJ. Phosphodiesterasa-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-75.